In addition, IL-4-blockade had a significantly inhibitory impact on pancreatic cancer progression, where IL-4 neutralizing antibody was proven to inhibit the basal growth of COLO-357, PANC-1, and MIA PaCa-2 cells [54]. The gene discussed is IL4; the disease is familial pancreatic carcinoma.